Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Basil refers to aromatic herbs of the genus *Ocimum*, primarily *Ocimum basilicum* (sweet basil) and *Ocimum sanctum* (holy basil or tulsi). In clinical and pharmacological research, basil is investigated for its antioxidant, anti-inflammatory, and antimicrobial properties, attributed to bioactive constituents such as rosmarinic acid, orientin, linalool, and methyl chavicol. It is studied in various forms, including dried leaves for dietary intervention in cardiovascular and metabolic health, and concentrated extracts for conditions like recurrent aphthous stomatitis (oral ulcers), dyspepsia, and cognitive enhancement. Preclinical studies suggest that holy basil can reduce gastric acid secretion and increase mucus production, while its antioxidant profile helps neutralize free radicals and modulate inflammatory cytokines like IL-6 and TNF-alpha.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on basil (Alasht Pharmed).